文献速递皮肤肿瘤

退伍军人晚期黑色素瘤相对比例增加:与监测、流行病学和最终结果登记处的比较分析

Increased relative proportions of advanced melanoma among veterans: A comparative analysis with the Surveillance, Epidemiology, and End Results registry.
PubMed 文献 · J Am Acad Dermatol · 2022-05-17

该研究比较了2009至2017年退伍军人事务部癌症登记处(VACR)15334例与SEER登记处166265例黑色素瘤患者。退伍军人更常表现为区域或远处病变(17.5% vs 13.0%)。除≥80岁诊断者外,VACR各年龄组5年黑色素瘤特异性生存(MSS)均低于SEER;2015-2017年诊断的IV期患者2年MSS从VACR的37.8%升至51.5%,SEER从36.4%升至44.8%。

要点

  • 退伍军人黑色素瘤患者区域或远处病变比例为17.5%,高于SEER的13.0%。
  • 除≥80岁诊断者外,VACR各年龄组5年MSS均低于SEER。
  • 2015-2017年IV期2年MSS:VACR 51.5%,SEER 44.8%。

核心结论

  • 与SEER相比,退伍军人黑色素瘤诊断时分期更晚;但两者IV期MSS近期均有改善。

研究设计与样本

  • 数据来自退伍军人事务部癌症登记处(VACR)和SEER(18个登记处),纳入2009至2017年黑色素瘤患者,比较人口学、肿瘤特征和黑色素瘤特异性生存(MSS)。

主要发现

  • 共识别15334例退伍军人和166265例SEER黑色素瘤患者。
  • 退伍军人更常表现为区域或远处病变(17.5% vs 13.0%)。
  • 除≥80岁诊断者外,VACR各年龄组5年MSS均低于SEER。
  • 2009至2017年,VACR各分期MSS均低于SEER。
  • 2015-2017年诊断的IV期黑色素瘤2年MSS从VACR的37.8%升至51.5%,SEER从36.4%升至44.8%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 退伍军人独特的人口学特征和VACR固有的缺失数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Surveillance, Epidemiology, and End Results (SEER) program reflects a third of the population of the United States. However, SEER may not be generalizable to the veteran population. Because veterans comprise a high-risk population, this discrepancy may limit our understanding of the epidemiology of melanoma in such high-risk populations. OBJECTIVES: To assess differences in demographics, tumor characteristics, and melanoma-specific survival (MSS) in veterans compared to the general population. METHODS: Data were collected from the Veterans Affairs Cancer Registry (VACR) and SEER (18 registries) from 2009 to 2017. RESULTS: We identified 15,334 veterans and 166,265 SEER patients with melanoma. Veterans were more likely to present with regional or distant disease (17.5% vs 13.0% in SEER). In VACR relative to SEER, the 5-year MSS was lower across all ages, except those diagnosed at ≥80 years. From 2009 to 2017, MSS by stage was lower across all stages in VACR. However, for stage IV melanomas diagnosed in 2015 to 2017 compared to 2011-2014, 2-year MSS increased from 37.8% to 51.5% in VACR versus 36.4% to 44.8% in SEER. LIMITATIONS: Unique veteran demographics and missing data inherent to VACR. CONCLUSION: Compared to SEER, veterans with melanoma were diagnosed at later stages; however, both exhibited recent improvement in stage IV MSS.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Chang MS, La J, Trepanowski N, et al. Increased relative proportions of advanced melanoma among veterans: A comparative analysis with the Surveillance, Epidemiology, and End Results registry. J Am Acad Dermatol. 2022. PMID: 35595121. doi:10.1016/j.jaad.2022.02.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。